GPM Growth Investors Inc. Trims Position in Johnson & Johnson (NYSE:JNJ)

Share on StockTwits

GPM Growth Investors Inc. trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.6% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 14,941 shares of the company’s stock after selling 715 shares during the period. Johnson & Johnson makes up about 1.5% of GPM Growth Investors Inc.’s holdings, making the stock its 29th biggest holding. GPM Growth Investors Inc.’s holdings in Johnson & Johnson were worth $2,224,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Lake Point Wealth Management increased its holdings in shares of Johnson & Johnson by 144.4% during the 1st quarter. Lake Point Wealth Management now owns 286 shares of the company’s stock worth $38,000 after buying an additional 169 shares during the last quarter. Islay Capital Management LLC acquired a new stake in shares of Johnson & Johnson during the 2nd quarter worth $42,000. FAI Wealth Management increased its holdings in shares of Johnson & Johnson by 45.9% during the 2nd quarter. FAI Wealth Management now owns 321 shares of the company’s stock worth $45,000 after buying an additional 101 shares during the last quarter. SeaBridge Investment Advisors LLC increased its holdings in shares of Johnson & Johnson by 160.0% during the 2nd quarter. SeaBridge Investment Advisors LLC now owns 325 shares of the company’s stock worth $46,000 after buying an additional 200 shares during the last quarter. Finally, Crewe Advisors LLC increased its holdings in shares of Johnson & Johnson by 909.1% during the 3rd quarter. Crewe Advisors LLC now owns 333 shares of the company’s stock worth $50,000 after buying an additional 300 shares during the last quarter. Institutional investors and hedge funds own 67.44% of the company’s stock.

Shares of Johnson & Johnson stock opened at $148.10 on Friday. The business has a 50-day moving average of $148.57 and a 200-day moving average of $146.59. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.25 and a quick ratio of 0.99. The company has a market capitalization of $389.92 billion, a PE ratio of 23.29, a P/E/G ratio of 3.36 and a beta of 0.68. Johnson & Johnson has a 1-year low of $109.16 and a 1-year high of $157.00.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Sunday, October 18th. The company reported $2.20 earnings per share for the quarter, beating the consensus estimate of $1.98 by $0.22. Johnson & Johnson had a return on equity of 35.21% and a net margin of 22.69%. The company had revenue of $21.08 billion during the quarter, compared to the consensus estimate of $20.15 billion. During the same period last year, the firm earned $2.12 earnings per share. The company’s revenue was up 1.7% on a year-over-year basis. On average, equities analysts expect that Johnson & Johnson will post 8 earnings per share for the current fiscal year.

In other news, EVP Kathryn E. Wengel sold 16,115 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the transaction, the executive vice president now owns 66,658 shares of the company’s stock, valued at $10,233,336.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Ashley Mcevoy sold 29,000 shares of the stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $147.47, for a total transaction of $4,276,630.00. Following the transaction, the executive vice president now directly owns 21,682 shares in the company, valued at approximately $3,197,444.54. The disclosure for this sale can be found here. Company insiders own 0.27% of the company’s stock.

JNJ has been the subject of several recent research reports. Raymond James increased their price target on Johnson & Johnson from $157.00 to $158.00 and gave the company an “outperform” rating in a report on Friday, July 17th. ValuEngine upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Monday, August 3rd. SVB Leerink reiterated an “outperform” rating on shares of Johnson & Johnson in a report on Wednesday, July 15th. Independent Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and increased their price target for the company from $161.00 to $164.00 in a report on Monday, July 20th. Finally, Credit Suisse Group increased their price target on Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a report on Wednesday. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $164.93.

Johnson & Johnson Company Profile

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Article: Market Indexes

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Foster Victor Wealth Advisors LLC Invests $4.30 Million in TE Connectivity Ltd.
Foster Victor Wealth Advisors LLC Invests $4.30 Million in TE Connectivity Ltd.
Krueger & Catalano Capital Partners LLC Trims Holdings in NVIDIA Co.
Krueger & Catalano Capital Partners LLC Trims Holdings in NVIDIA Co.
Krueger & Catalano Capital Partners LLC Sells 526 Shares of Unilever NV
Krueger & Catalano Capital Partners LLC Sells 526 Shares of Unilever NV
Mayfair Advisory Group LLC Increases Position in JPMorgan Chase & Co.
Mayfair Advisory Group LLC Increases Position in JPMorgan Chase & Co.
Nottingham Advisors Inc. Boosts Stock Holdings in iShares US Preferred Stock ETF
Nottingham Advisors Inc. Boosts Stock Holdings in iShares US Preferred Stock ETF
NewFocus Financial Group LLC Cuts Position in Becton, Dickinson and Company
NewFocus Financial Group LLC Cuts Position in Becton, Dickinson and Company


 
© 2006-2020 Zolmax.